BIOCON | LUPIN | BIOCON / LUPIN |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 40.5 | -58.9 | - | View Chart |
P/BV | x | 5.3 | 2.3 | 229.9% | View Chart |
Dividend Yield | % | 0.0 | 0.9 | - |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BIOCON Mar-21 |
LUPIN Mar-21 |
BIOCON / LUPIN |
5-Yr Chart Click to enlarge
|
||
High | Rs | 488 | 1,122 | 43.5% | |
Low | Rs | 275 | 576 | 47.7% | |
Sales per share (Unadj.) | Rs | 59.2 | 334.2 | 17.7% | |
Earnings per share (Unadj.) | Rs | 7.7 | 27.0 | 28.5% | |
Cash flow per share (Unadj.) | Rs | 13.7 | 46.6 | 29.3% | |
Dividends per share (Unadj.) | Rs | 0 | 6.50 | 0.0% | |
Avg Dividend yield | % | 0 | 0.8 | 0.0% | |
Book value per share (Unadj.) | Rs | 62.3 | 300.1 | 20.8% | |
Shares outstanding (eoy) | m | 1,200.00 | 453.68 | 264.5% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 6.4 | 2.5 | 253.4% | |
Avg P/E ratio | x | 49.4 | 31.4 | 157.4% | |
P/CF ratio (eoy) | x | 27.9 | 18.2 | 153.1% | |
Price / Book Value ratio | x | 6.1 | 2.8 | 216.4% | |
Dividend payout | % | 0 | 24.0 | 0.0% | |
Avg Mkt Cap | Rs m | 457,350 | 385,072 | 118.8% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 17,410 | 28,259 | 61.6% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 71,058 | 151,630 | 46.9% | |
Other income | Rs m | 6,052 | 1,363 | 444.1% | |
Total revenues | Rs m | 77,110 | 152,993 | 50.4% | |
Gross profit | Rs m | 13,145 | 25,669 | 51.2% | |
Depreciation | Rs m | 7,151 | 8,874 | 80.6% | |
Interest | Rs m | 577 | 1,406 | 41.0% | |
Profit before tax | Rs m | 11,469 | 16,751 | 68.5% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,215 | 4,485 | 49.4% | |
Profit after tax | Rs m | 9,254 | 12,266 | 75.4% | |
Gross profit margin | % | 18.5 | 16.9 | 109.3% | |
Effective tax rate | % | 19.3 | 26.8 | 72.1% | |
Net profit margin | % | 13.0 | 8.1 | 161.0% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 76,004 | 139,864 | 54.3% | |
Current liabilities | Rs m | 42,101 | 84,361 | 49.9% | |
Net working cap to sales | % | 47.7 | 36.6 | 130.3% | |
Current ratio | x | 1.8 | 1.7 | 108.9% | |
Inventory Days | Days | 137 | 69 | 197.4% | |
Debtors Days | Days | 63 | 108 | 58.1% | |
Net fixed assets | Rs m | 106,142 | 94,439 | 112.4% | |
Share capital | Rs m | 6,000 | 907 | 661.2% | |
"Free" reserves | Rs m | 68,728 | 135,229 | 50.8% | |
Net worth | Rs m | 74,728 | 136,136 | 54.9% | |
Long term debt | Rs m | 29,616 | 161 | 18,372.2% | |
Total assets | Rs m | 182,146 | 234,302 | 77.7% | |
Interest coverage | x | 20.9 | 12.9 | 161.7% | |
Debt to equity ratio | x | 0.4 | 0 | 33,469.7% | |
Sales to assets ratio | x | 0.4 | 0.6 | 60.3% | |
Return on assets | % | 5.4 | 5.8 | 92.5% | |
Return on equity | % | 12.4 | 9.0 | 137.4% | |
Return on capital | % | 11.5 | 13.3 | 86.7% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 7.2 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | 5,084 | NA | - | |
Fx inflow | Rs m | 11,791 | 51,027 | 23.1% | |
Fx outflow | Rs m | 5,084 | 21,081 | 24.1% | |
Net fx | Rs m | 6,707 | 29,946 | 22.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 11,597 | 18,218 | 63.7% | |
From Investments | Rs m | -36,247 | -12,396 | 292.4% | |
From Financial Activity | Rs m | 25,640 | -18,853 | -136.0% | |
Net Cashflow | Rs m | 723 | -13,031 | -5.5% |
Indian Promoters | % | 39.7 | 46.5 | 85.4% | |
Foreign collaborators | % | 20.9 | 0.3 | 7,467.9% | |
Indian inst/Mut Fund | % | 24.0 | 41.9 | 57.3% | |
FIIs | % | 15.6 | 14.7 | 106.6% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 39.4 | 53.2 | 74.0% | |
Shareholders | 347,911 | 378,547 | 91.9% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare BIOCON With: CIPLA SUN PHARMA DR. REDDYS LAB AUROBINDO PHARMA ZYDUS LIFESCIENCES
After opening the day higher, Indian share markets extended gains as the session progressed and ended near the day's high.
Recent developments in digital healthcare and revised targets by brokerages send Lupin shares flying.
The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?
For the Nifty pharma index, it seems as if bulls are losing ground as they witness multiple bearish candlestick patterns.
The strong momentum in India's IPO market is poised to continue with the market regulator approving the IPOs of three firms including PharmEasy.
In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.
More Views on NewsWe are just two months into 2022 and several penny stocks that we track have already surged 5x.
Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.
A step-by-step method to pick the best penny stocks for the long term.
These penny stocks can become future multibaggers. Watch out for them.
Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?
More